Australia's most trusted
source of pharma news
Wednesday, 30 April 2025
Posted 18 May 2023 AM
A handful of new agents with blockbuster potential recently approved by overseas jurisdictions hints at what's on the cards for Australia in 2023 - and into next year.
A recent Evaluate Vantage analysis shows the launch of six products - mostly in the US - is already underway, and there's no shortage of pending regulatory news for the remainder of the year, according to the analytics company.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.